CHMP Backs Rurioctocog alfa pegol (Adynovi) for Hemophilia A

The European Medicines Agency committee recommended approval of rurioctocog alfa pegol for the treatment and prophylaxis of bleeding in patients aged 12 years and older with hemophilia A.
International Approvals